Klaria Pharma

First quarter of 2024

The group in total

- Net sales 0.0 MSEK (0.0 MSEK)

- Other income 0.0 MSEK (0.3 MSEK)

- R&D expenses for the quarter amounted to 0.5 MSEK (7.0 MSEK)

- Profit after tax amounted to -12.4 MSEK (-5.4 MSEK)

- Earnings per share for the quarter amounted to -0.11 SEK (-0.10 SEK)

- Cash flow from operating activities amounted to -2.0 MSEK (-2.2 MSEK)

- Liquid assets on the balance sheet date amounted to 0.5 MSEK (8.9 MSEK)

- Equity as of June 30 amounted to 20.8 MSEK (60.6 MSEK)

The period January-June 2024

The group in total

- Net sales 0.0 MSEK (6.5 MSEK)

- Other income 0.0 MSEK (0.3 MSEK)

- R&D expenses for the quarter amounted to 1.5 MSEK (15.6 MSEK)

- Profit after tax amounted to -24.3 MSEK (-15.5 MSEK)

- Earnings per share for the period amounted to -0.22 SEK (-0.16 SEK)

- Cash flow from operating activities amounted to -9.8 MSEK (-11.3 MSEK)

This interim report has been prepared for the group in accordan ce with IAS 34 Interim Reporting and the Annual Accounts Act (ÅRL) as well as IFRS, as adopted by the EU. For the parent company, the Annual Accounts Act (ÅRL) and the Council for Financial Reporting Recommendation RFR 2 Accounting for legal entities have been applied.